On Monday, Unicycive Therapeutics Inc (NASDAQ: UNCY) was 4.26% up from the session before settling in for the closing price of $0.53. A 52-week range for UNCY has been $0.20 – $1.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -5.80% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 59.82%. With a float of $85.84 million, this company’s outstanding shares have now reached $103.80 million.
In an organization with 14 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 235.06%, operating margin of 10763.47%, and the pretax margin is 8487.82%.
Unicycive Therapeutics Inc (UNCY) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Unicycive Therapeutics Inc stocks. The insider ownership of Unicycive Therapeutics Inc is 17.30%, while institutional ownership is 51.94%.
Unicycive Therapeutics Inc (UNCY) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.13 earnings per share (EPS) during the time that was better than consensus figure (set at -0.13) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.82% per share during the next fiscal year.
Unicycive Therapeutics Inc (NASDAQ: UNCY) Trading Performance Indicators
You can see what Unicycive Therapeutics Inc (UNCY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Unicycive Therapeutics Inc (UNCY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.08 million. That was inferior than the volume of 1.23 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.56%. Additionally, its Average True Range was 0.05.
During the past 100 days, Unicycive Therapeutics Inc’s (UNCY) raw stochastic average was set at 85.93%, which indicates a significant increase from 70.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.63% in the past 14 days, which was lower than the 114.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4461, while its 200-day Moving Average is $0.7668. However, in the short run, Unicycive Therapeutics Inc’s stock first resistance to watch stands at $0.5642. Second resistance stands at $0.5757. The third major resistance level sits at $0.5928. If the price goes on to break the first support level at $0.5356, it is likely to go to the next support level at $0.5185. The third support level lies at $0.5070 if the price breaches the second support level.
Unicycive Therapeutics Inc (NASDAQ: UNCY) Key Stats
There are 103,796K outstanding shares of the company, which has a market capitalization of 57.59 million. As of now, sales total 680 K while income totals -30,540 K. Its latest quarter income was 0 K while its last quarter net income were -4,100 K.
